With Phase 2 data in chronic cough imminent, $BLU benchmark: 

&gt; 30% placebo adjusted cough reduction
&lt;5% taste side effect

Bellus has shown best in class P2X3 &amp; P2X2/3 selectivity vs competitors $MRK $BAYRY Shionogi https://t.co/BuXvuE4Hsv